¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"population attributable risk"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • risk benefit ratio
    À§ÇèÆíÀͺñ
  • risk difference
    À§ÇèµµÂ÷ÀÌ
  • risk factor
    À§ÇèÀÎÀÚ
  • risk management
    À§Çèµµ°ü¸®
  • risk marker
    À§ÇèÇ¥ÁöÀÚ
  • risk ratio
    À§Çèºñ
  • dynamic population
    À¯µ¿Àα¸
  • island population
    °í¸³Àα¸Áý´Ü
  • infinite population
    ¹«ÇѸðÁý´Ü
  • model population
    ¸ðÇüÀα¸
  • natural population
    ÀÚ¿¬Áý´Ü
  • population
    1. Àα¸ 2. ¸ðÁý´Ü, Áý´Ü
  • population density
    Àα¸¹Ðµµ
  • population dynamics
    Àα¸µ¿ÅÂ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • natural population
    ÀÚ¿¬Áý´Ü, ÀÚ¿¬°³Ã¼±º
  • population
    Àα¸, ¸ðÁý´Ü
  • population policy
    Àα¸Á¤Ã¥
  • population pyramid
    Àα¸¸ðÇü, Àα¸ÇǶó¹Ìµå
  • population study
    Àα¸Á¶»ç
  • population trend
    Àα¸Ãß¼¼
  • population variance
    ¸ðÁý´ÜºÐ»ê
  • population excess rate
    ¸ðÁý´ÜÃʰúÀ²
  • population mortality table
    ±¹¹Î»ç¸Á·üÇ¥
  • reference population
    ±âÁØÁý´Ü
  • stable population
    ¾ÈÁ¤Àα¸
  • standard population
    Ç¥ÁØÀα¸
  • stationary population
    Á¤ÁöÀα¸
  • target population
    Ç¥ÀûÁý´Ü
  • virgin population
    ¹«³ëÃâÀα¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • population density
    Àα¸¹Ðµµ(ÊÙËÑ̬).
  • population dynamics
    Áý´Üµ¿ÅÂ, Àα¸µ¿·ÂÇÐ(ÊÙËÄËç̰).
  • population equivalent
    Àα¸´ç·®(ÊÙËÀËâ).
  • population genetics
    Áý´ÜÀ¯ÀüÇÐ(ÊÙËôËøÌ°).
  • population growth
    Àα¸¼ºÀå(ËöË´ËÛËö).
  • population increase
    Àα¸Áõ°¡(ÊÙ̡˧).
  • population mean
    ¸ðÆò±Õ(ËḬ̂˻).
  • population mortality table
    ±¹¹Î»ý¸íÇ¥(Ë´ËÑË×ËḬ̂), ±¹¹Î»ç¸Á·üÇ¥(Ë´ËÑË×ËÎ Ëô̰).
  • population mutation
    Áý´Ü±ºµ¹¿¬º¯ÀÌ(¡­ÔÍæÔܨì¶).
  • population policy
    Àα¸Á¤Ã¥(ÊÙËøÌ¤).
  • population problem
    Àα¸¹®Á¦.
  • population pyramid
    Àα¸¸ðÇü(ËöË´ËÎÌ´).
  • population screening
    Áý´Ü°ËÁø(̤ËÀ˧̤).
  • population study
    Àα¸Á¶»ç
  • population trend
    Àα¸Ãß¼¼(ÊÙ̧ËÛ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • radiation risk coeffecient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • recurrence risk
    Àç¹ßÀ§Çè
  • relative risk
    ºñ±³À§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ(ËÓË´Ëô̴̬).
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • risk factor
    À§ÇèÀÎÀÚ
  • risk factors
  • risk management
    À§Çè°ü¸®.
  • risk-benefit analysis
    À§Çè-À̵æºÐ¼®
  • surgical risk
    ¼ö¼úÀ§Çèµµ(¼ö¼úÀ§ÇèŹ).
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸¼º »ó´ëÀ§Çè¸ðµ¨
  • asynchronous population
    ºñµ¿Á¶(¼¼Æ÷)Áý´Ü
  • bacterial population
    ¼¼±ÕÁý´Ü
  • composition of population
    Àα¸±¸¼º(ËöË´ Ë´ËÛ).
  • infinite population
    ¹«ÇѸðÁý´Ü.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
AF abnormal frequency; acid-fast; adult female; afebrile; aflatoxin; albumin-free; albumose-free; aldeh...
CPDL cumulative population doubling level
CPK cell population kinetic [model]; creatine phosphokinase
CPS carbamoylphosphate synthetase; cardioplegic perfusion solution; centipoise; cervical pain syndrome; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NPHS National Population Health Survey
POHEM POpulation HEalth Model
PD Population doublings
pEPSP population excitatory postsynaptic potential
PS Population spike
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • risk
    À§Çè, À§Çèµµ, À§Ç輺
  • risk factor
    À§Çè ¿äÀÎ, À§Çè ¿ä¼Ò, À§Çè ÀÎÀÚ
    °³ÀÎÀ̳ª ´Üü°¡ ÁúȯÀ̳ª Àå¾Ö¿¡ °É¸®±â ½±°Ô ÇÏ´Â ¿øÀÎÀÌ µÇ´Â ¿ä¼Ò·Î¼­ ¹Î°¨ÇÑ »ç¶÷µé¿¡¼­ ¹ß»ý ºóµµ¿Í Á¤µµ¸¦ Áõ°¡½ÃŲ´Ù.
  • risk management
    ¼úÀÚÀÇ ¾ÈÀü ¼öÄ¢
  • risk principle
    À§Çèµµ ¿ø¸®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
population surveillance <epidemiology> Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy.
(12 Dec 1998)
suburban population The inhabitants of peripheral or adjacent areas of a city or town.
(12 Dec 1998)
synchronous cell population <cell culture> A culture of cells that all divide in synchrony.
Particularly useful for certain studies of the cell cycle, cells can be made synchronous by depriving them of essential molecules, which are then restored. Synchronisation breaks down after a few cycles, however, as individual cells have unique division rates.
(19 Jan 1998)
q in population genetics The frequency of the less common of two different alternative (allelic) versions of a gene. (the frequency of the more common allele is p).
(12 Dec 1998)
topotypical population <zoology> Population occurring at the type locality from which the type specimen was taken.
(09 Jan 1998)
urban population The inhabitants of a city or town, including metropolitan areas and suburban areas.
(12 Dec 1998)
absolute risk <statistics> The excess risk due to exposure to a specific hazard (disease, injury, etc.)
(15 Jan 1998)
acceptable risk <statistics> This relates to the potential for suffering disease or injury that will be tolerated by an individual, group, or society in exchange for the benefits of using a substance or process that will cause such disease or injury.
Acceptability of risk depends on scientific data, social, economic, and political factors, and on the perceived benefits arising from a chemical or process that creates the risk in question.
(15 Jan 1998)
cardiac risk A term to describe overall risk of developing heart disease (blockage of the coronary arteries). Typical risk factors include: diabetes, high blood pressure, prior heart attack, high cholesterol, obesity, smoking and a family history for heart attacks in parents or siblings.
(27 Sep 1997)
recurrence risk In medical genetics, the recurrence risk is the chance that a genetic (inherited) disease present in the family will recur in that family and affect another person (or persons). It is the chance of lightning striking twice (or thrice, etc.).
(12 Dec 1998)
glaucoma, risk factors If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites).
(12 Dec 1998)
relative risk <epidemiology> The proportion of diseased people amongst those exposed to the relevant risk factor divided by the proportion of diseased people amongst those not exposed to the risk factor. This should be used in those cohort studies where those with and without disease are followed to observe which individuals become diseased.
(05 Dec 1998)
risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
(12 Dec 1998)
risk assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences.
(12 Dec 1998)
risk benefit An analysis of risk versus benefit is a complex assessment that must be made by a physician prior to the administration of a particular form of drug therapy. Since many medications may have side effects that can be harmful (during the course of treatment), the overall risk of a particular form of drug therapy must be weighed against the overall threat of the untreated disease process (or treatment with an altenative drug).
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • risk
    À§Çè(¼º);¸ðÇè;À§Çè(·ü);º¸Çè±Ý(¾×);ÇǺ¸ÇèÀÚ(¹°);À§Å·ӰÔÇÏ´Ù;¸ðÇèÇÏ´Ù;(À§ÇèµîÀ»)°¢¿ÀÇϰí ÀÖ´Ù;°¨ÇàÇÏ´Ù;°¨È÷...ÇÏ´Ù
  • risk capital
    =VENTURE CAPITAL
  • risk manager
    º¸Çè ´ã´ç ÀÓÁ÷¿ø
  • risk-benefit ratio
    À§Ç輺°ú ¼öÀͼº°úÀÇ ºñÀ²
  • risk-money
    ºÎÁ·±Ý º¸»ó ¼ö´ç(ÀºÇà µî¿¡¼­ Ãâ³³°è¿ø¿¡°Ô ÁÖ´Â)
  • security risk
    (Ä¡¾È»óÀÇ)À§Çè Àι°
  • war risk insurance
    ÀüÀï º¸Çè
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á